ERBB2 and non-small cell lung carcinoma: In addition, in various cancer types like NSCLC, breast, colorectal, bladder, gastric, and esophageal cancers, HER2 mutations, particularly exon 20 insertions, lead to constitutive tyrosine kinase activation, driving oncogenesis without ligand stimulation (3, 5, 20–23).